Journal
ACTA BIOMATERIALIA
Volume 80, Issue -, Pages 296-307Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2018.09.017
Keywords
W18O49; Platelet membrane; Metformin; Tumor hypoxia; Photodynamic therapy; Photothermal therapy
Funding
- Jiangsu Province Health and Family Planning Commission Youth Scientific Research Project [Q201508]
- Natural Science Foundation of Jiangsu Province [BK20150109]
- Six Talent Peaks Project of Jiangsu Province [2015-WSN-079]
- Medical Science and technology development Foundation Nanjing [YKK15067, QRX11178]
- Jiangsu province key medical young talents, 13th Five-Year health promotion project of Jiangsu province [QNRC2016041]
Ask authors/readers for more resources
W18O49-mediated photodynamic therapy (PDT) and photothermal therapy (PTT) are limited by the easily oxidized property and tumor hypoxia. Here, we report the development of platelet membranes as nanocarriers to co-load W18O49 nanoparticles (NPs) and metformin (PM-W18O49-Met NPs). Platelet membranes can protect W18O49 from oxidation and immune evasion, and increase the accumulation of W18O49 in tumor sites via the passive EPR effect and active adhesion between platelets and cancer cells. The introduction of metformin (Met), a typical anti-diabetic drug, can alleviate the tumor hypoxia through reducing oxygen consumption. As a result, ROS and heat generation are both greatly increased, as revealed by ROS/hypoxia imaging in vitro, IR thermal imaging in vivo and PET imaging in vivo. PM-W18O49-Met NPs show the improved therapeutic effects with greatly inhibited tumor growth and induced tumor cell apoptosis. Therefore, our work provides a novel strategy for simultaneous enhanced PDT and PTT, which is promising in bioapplication. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available